Modified AAV capsid proteins and uses thereof
Adeno associated viral (AAV) particles are emerging as useful vehicle for gene delivery to various organs and tissues, one of them being the retina. Provided here are variant AAV (e.g., variant serotype 2 (AAV2)) capsid proteins and variant capsid protein containing particles with enhanced ability to transduce retinal cells.
1. A variant recombinant adeno-associated virus (rAAV) capsid protein comprising any one of the following combinations of amino acid substitutions:
(a) asparagine, alanine, aspartic acid, glycine, glutamic acid, aspartic acid, and phenylalanine at positions corresponding to amino acids 263, 264, 492, 493, 494, 499, and 500 of AAV2 VP1 capsid protein, respectively, and SAAGADXAXDS (SEQ ID NO: 5) at positions corresponding to amino acids 546-556 of AAV2 VP1 capsid protein;
(b) alanine, threonine, proline, aspartic acid, phenylalanine, and aspartic acid at positions corresponding to amino acids 263, 490, 492, 499, 500, and 530 of AAV2 VP1 capsid protein, respectively;
(c) asparagine, alanine, phenylalanine, alanine, asparagine, valine, threonine, arginine, aspartic acid, and aspartic acid at positions corresponding to amino acids 263, 264, 444, 451, 454, 455, 459, 527, 530, and 531 of AAV2 VP1 capsid protein, respectively;
(d) aspartic acid, glycine, glutamic acid, aspartic acid, and phenylalanine at positions corresponding to amino acids 492, 493, 494, 499, and 500 of AAV2 VP1 capsid protein, respectively, and EDATENXIXXDR (SEQ ID NO: 4) at positions corresponding to amino acids 545-556 of AAV2 VP1 capsid protein;
(e) alanine, glutamine, aspartic acid, glutamic acid, phenylalanine, and proline at positions corresponding to amino acids 263, 491, 492, 494, 500, and 503 of AAV2 VP1 capsid protein, respectively; or
(f) phenylalanine, GAXNMXTXAXR (SEQ ID NO: 31), threonine, proline, aspartic acid, phenylalanine, and aspartic acid at positions corresponding to amino acids 444, 451-461, 490, 492, 499, 500, and 530 of AAV2 VP1 capsid protein, respectively;
wherein each X corresponds to amino acids of a wild-type AAV2 VP1 capsid sequence as set forth in SEQ ID NO: 1, or homologous amino acids of a wild-type VP1 capsid sequence of an AAV serotype other than AAV2.
2. The rAAV capsid protein of claim 1 , comprising (a) aspartic acid, glycine, glutamic acid, aspartic acid, and phenylalanine at positions corresponding to amino acids 492, 493, 494, 499, and 500 of AAV2 capsid protein, respectively, and SAAGADXAXDS (SEQ ID NO: 5) at positions corresponding to amino acids 546-556 of AAV2 capsid protein.
3. The rAAV capsid protein of claim 2 , wherein the capsid protein is of serotype 2 and wherein the capsid protein comprises the amino acid sequence of SEQ ID NO: 12.
4. The rAAV capsid protein of claim 2 , further comprising phenylalanines at positions corresponding to amino acids 444 and 730 of AAV2 capsid protein.
5. The rAAV capsid protein of claim 4 , further comprising a phenylalanine at a position corresponding to amino acid 272 of AAV2 capsid protein.
6. The rAAV capsid protein of claim 5 , wherein the capsid protein is of serotype 2.
7. The rAAV capsid protein of claim 5 , further comprising a valine at a position corresponding to 491 of AAV2 capsid protein.
8. The rAAV capsid protein of claim 7 , wherein the capsid protein is of serotype 2.
9. The rAAV capsid protein of claim 1 , comprising (b) alanine, threonine, proline, aspartic acid, phenylalanine, and aspartic acid at positions corresponding to amino acids 263, 490, 492, 499, 500, and 530 of AAV2 capsid protein, respectively.
10. The rAAV capsid protein of claim 9 , wherein the capsid protein is of serotype 2 and comprises the amino acid sequence of SEQ ID NO: 24.
11. The rAAV capsid protein of claim 1 , comprising (c) asparagine, alanine, phenylalanine, alanine, asparagine, valine, threonine, arginine, aspartic acid, and aspartic acid at positions corresponding to amino acids 263, 264, 444, 451, 454, 455, 459, 527, 530, and 531 of AAV2 capsid protein, respectively.
12. The rAAV capsid protein of claim 11 , wherein the capsid protein is of serotype 2 and comprises the amino acid sequence of SEQ ID NO: 25.
13. The rAAV capsid protein of claim 1 , comprising (d) aspartic acid, glycine, glutamic acid, aspartic acid, and phenylalanine at positions corresponding to amino acids 492, 493, 494, 499, and 500 of AAV2 capsid protein, respectively, and EDATENXIXXDR (SEQ ID NO: 4) at positions corresponding to amino acids 545-556 of AAV2 capsid protein.
14. The rAAV capsid protein of claim 13 , wherein the capsid protein is of serotype 2 and comprises the amino acid sequence of SEQ ID NO: 11.
15. The rAAV capsid protein of claim 1 , comprising (e) alanine, glutamine, aspartic acid, glutamic acid, phenylalanine, and proline at positions corresponding to amino acids 263, 491, 492, 494, 500, and 503 of AAV2 capsid protein, respectively.
16. The rAAV capsid protein of claim 15 , wherein the capsid protein is of serotype 2 and comprises the amino acid sequence of SEQ ID NO: 27 further comprising an alanine at a position corresponding to amino acid 263 of AAV2 capsid protein.
17. The rAAV capsid protein of claim 1 , comprising (f) phenylalanine, GAXNMXTXAXR (SEQ ID NO: 31), threonine, proline, aspartic acid, phenylalanine, and aspartic acid at positions corresponding to amino acids 444, 451-461, 490, 492, 499, 500, and 530 of AAV2 capsid protein, respectively.
18. The rAAV capsid protein of claim 17 , wherein the capsid protein is of serotype 2 and comprises an amino acid sequence corresponding to the amino acid sequence of AAV2 variant P3-PR3.
19. A recombinant AAV (rAAV) particle comprising the rAAV capsid protein of claim 1 .
20. The rAAV particle of claim 19 , further comprising a nucleic acid comprising inverted terminal repeats (ITRs) and a gene of interest.